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Abstract
Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent
studies have suggested that extreme levels of genomic aberrations may be beneficial for the survival outcome for patients
with specific tumour types. We investigated the extent of genomic instability in predominantly high-grade serous ovarian
cancers (SOC) using two independent datasets, generated in Norway (n = 74) and Australia (n = 70), respectively. Genomic
instability was quantified by the Total Aberration Index (TAI), a measure of the abundance and genomic size of copy
number changes in a tumour. In the Norwegian cohort, patients with TAI above the median revealed significantly
prolonged overall survival (p,0.001) and progression-free survival (p,0.05). In the Australian cohort, patients with above
median TAI showed prolonged overall survival (p,0.05) and moderately, but not significantly, prolonged progression-free
survival. Results were confirmed by univariate and multivariate Cox regression analyses with TAI as a continuous variable.
Our results provide further evidence supporting an association between high level of genomic instability and prolonged
survival of high-grade SOC patients, possibly as disturbed genome integrity may lead to increased sensitivity to
chemotherapeutic agents.
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Introduction
Serous ovarian cancers (SOC) are highly aggressive but often
chemosensitive tumours, characterised by substantial morpholog-
ical heterogeneity, frequent genomic aberrations, and genomic
instability (see reviews by [1–3]). Most patients are diagnosed at an
advanced stage of the disease [4], and almost half of all women
(46%) diagnosed with SOC die within five years (http://seer.
cancer.gov). Clinical and pathological classification methods,
including tumour grade and the extent of surgical debulking, still
fail to fully predict disease progression and patient outcome.
Microarray-based gene-expression profiling of tumours has
been used to discriminate between patients with good or
unfavourable prognosis and to categorize pathways for new
treatment strategies in epithelial ovarian cancer [5–12]. Previous
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studies have identified genomic regions of frequent copy number
change and mapped potential driver genes in high grade serous,
clear cell, and mucinous ovarian tumours [13–16]. Further,
amplified genes, including RAB25 and CCNE1, have been
associated with clinical parameters including histology, stage of
the disease, outcome, or therapy response [17–22]. Although there
has been some progress, prediction of clinical outcome for patients
with SOC remains imprecise and challenging.
Genomic instability is a hallmark of malignant tumours, causing
disturbed integrity of the genome, numerical alterations, and
structural changes. For various cancer types greater genomic
instability has been associated with poor prognosis, suggesting that
genomic instability may confer growth advantage of cancer cells
[23–25]. However, the effects of disordered genomic organization,
including defects in the regulation of mitoses, chromosomal
segregation, and spindle assembly, may also have an unfavourable
effect on the overall viability and fitness of cancer cells [26,27].
Consequently, there may be a critical level at which the
disadvantageous effects of genomic instability on patient survival
are outweighed by the detrimental effects on cancer cell viability.
This hypothesis is supported by recent studies on survival in breast,
ovarian, and other cancers, indicating a beneficial effect of
extreme genomic instability [28,29]. However, in most of these
studies genomic instability has only been estimated indirectly on
the basis of gene expression based signatures.
The capacity to repair genomic damage is crucial for cells to
react on DNA damaging agents. Allelic imbalance or mutations in
key checkpoint proteins result in impaired DNA repair and thus
suggests increased sensitivity to DNA damaging chemotherapeutic
drugs [30]. Thus, the extent of copy number variation may be an
indicator of malignancy on one hand and sensitivity to therapy on
the other. However, to measure directly the DNA repair capacity
of cell lines or clinical specimens is difficult to perform, since the
current genetic assays still lack high specificity [31].
In this study, we applied a numeric measure of genomic
instability, which we termed the Total Aberration Index (TAI), to
assess the level of genomic aberrations in SOC. Based on high-
throughput DNA copy number data, we investigated the
relationship between survival and the degree of genomic instability




The study including patients of the Norwegian cohort was
approved by the Regional Committees for Medical and Health
Research Ethics (REC) board (Reference No: S-01127). Exception
from written informed consent was given from the REC
authorities based on patients being deceased and all materials
used were remaining material after diagnosis. The study including
patients of the Australian cohort was approved by the Human
Research Ethics Committees at the Peter MacCallum Cancer
Centre, Queensland Institute of Medical Research, University of
Melbourne and all participating hospitals. Written informed
consent was obtained from all participants in this study.
Table 1. Clinicopathological characteristics of the Norwegian and Australian SOC patients.
Norwegian cohort Australian cohort
All TAI,med.1 TAI.med.1 p* All TAI,med.1 TAI.med.1 p*
Patients Total cases 74 (100%) 37 (50%) 37 (50%) 70 (100%) 35 (50%) 35 (50%)
Age Mean (SD) 60 (11) 60 (11) 60 (10) 57 (11) 55 (12) 58 (9)
Range 38–81 39–79 38–81 23–80 23–78 44–80
Age groups ,45 7 (10%) 4 (11%) 3 (8%) 0.711 6 (9%) 5 (14%) 1 (3%) 0.226
45–55 15 (20%) 6 (16%) 9 (24%) 25 (36%) 12 (34%) 13 (37%)
.55 52 (70%) 27 (73%) 25 (68%) 39 (56%) 18 (51%) 21 (60%)
Stage II 3 (4%) 1 (3%) 2 (5%) 0.958 0 (0%) 0 (0%) 0 (0%) 0.462
III (B+C) 50 (68%) 26 (70%) 24 (65%) 62 (89%) 30 (86%) 32 (91%)
IV 21 (28%) 10 (27%) 11 (30%) 8 (11%) 5 (14%) 3 (9%)
Grade 1 3 (4%) 2 (5%) 1 (3%) 0.186 4 (6%) 2 (6%) 2 (6%) 0.656
2 21 (28%) 7(19%) 14 (38%) 24 (34%) 10 (29%) 14 (40%)
3 50 (68%) 28(76%) 22 (60%) 40 (57%) 22 (63%) 18 (51%)
Chemotherapy Sensitive 51 (69%) 21 (57%) 30 (81%) 0.043 39 (56%) 17 (49%) 22 (63%) 0.336
Resistant 23 (31%) 16 (43%) 7 (19%) 31 (44%) 18 (51%) 13 (37%)
Progression Progression 69 (93%) 36 (97%) 33 (89%) 0.358 63 (90%) 3 (9%) 4 (11%) 1
No progression 5 (7%) 1 (3%) 4 (11%) 7 (10%) 32 (91%) 31 (87%)
PFS (months) Median 16 15 18 15 12 19
(95% CI) 14–21 10–18 15–26 11–20 10–19 13–23
OS (months) Median 32 25 50 40 25 47
(95% CI) 25–47 17–31 34–67 28–54 19–57 35–60
1Genomic instability was quantified as below (TAI,med.) or above (TAI.med.) median TAI. The median was 0.135 for the Norwegian cohort and 0.242 for the Australian
cohort.
*Calculated p-values for age, stage, and grade from Mann-Whitney tests and for chemotherapy and progression from Fisher’s exact tests.
Abbreviations: SOC, serous ovarian cancers; TAI, Total Aberration Index; PFS, progression-free survival; OS, overall survival; CI, confidence interval.
doi:10.1371/journal.pone.0054356.t001
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Figure 1. Examples of genomic profiles with low (left) and high (right) median Total Aberration Index (TAI). (a.) Examples from the
Norwegian and (b.) from the Australian cohort. The log2-transformed copy numbers of the chromosomes 1 to 23 are illustrated. The median was
0.135 for the Norwegian and 0.242 for the Australian cohort.
doi:10.1371/journal.pone.0054356.g001
Figure 2. Frequency of copy number changes in serous ovarian carcinomas of two independent cohorts. The frequencies of copy
number alterations in serous ovarian cancers of two independent cohorts from Norway and Australia are illustrated. Regions with copy number gains
are marked in red and regions with copy number losses are marked in green, respectively. (a) The frequency of copy number changes of 74 serous
ovarian tumours of the Norwegian cohort were determined using 42k cDNA arrays. Several high frequency peaks are visible, including gains at
regions on chromosome arms 1q, 3q, 8q, and 20q, and losses on chromosome arms 4q, 5q, 6 p, 8 p, 13, 16q, 18q, and the whole of the X
chromosome. (b) The frequency of aberrations of 70 ovarian tumour samples of the Australian cohort, as measured by 50 k SNP Affymetrix arrays. All
high frequency peaks of the Norwegian cohort are also identified in the Australian cohort, although some additional peaks appear in the Australian
data, e.g. gains in 1 p and losses on chromosome arms 17 p and 22q. The two data sets show high consistency in the aberration pattern, despite
differences in populations and analysis platforms (see also Figure 3).
doi:10.1371/journal.pone.0054356.g002
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Patient population and clinicopathological data
The Norwegian cohort, diagnosed and treated at the Depart-
ment of Gynecological Oncology at the Oslo University Hospital
The Norwegian Radiumhospital during the period May 1992 to
February 2003, consisted of 74 patients diagnosed with SOC on
routine pathology reports. All patients underwent primary surgery,
followed by adjuvant platinum-based chemotherapy. A summary
of the clinicopathological characteristics is shown in Table 1 and
detailed information is provided in Table S1 (see also [32]).
Progression-free survival (PFS) was defined as the time interval
that elapsed between diagnosis and progression, based on the first
confirmed sign of disease recurrence according to Gynecologic
Cancer InterGroup (GCIG) definitions. Overall survival was
defined as the time interval that elapsed between diagnosis and
death of any cause [32]. Sensitivity to platinum-based chemo-
therapy was defined as no relapse within six months after the
completion of the treatment.
The second cohort, originally analysed in Australia [33],
consisted of 70 patients diagnosed with SOC from 1988 to
2005, including 56 cases from Australia (from the Australian
Ovarian Cancer Study (AOCS) and the Gynaecological Oncology
Biobank at Westmead) and 14 cases from Japan. All patients
received first-line platinum-based chemotherapy. A summary of
the clinicopathological characteristics is shown in Table 1 and
additional information is provided in Table S2 (further genetic
information can be provided from AOCS Group on request). For
this cohort, PFS was defined as the time interval between the date
of diagnosis and the first confirmed sign of disease progression
based on GCIG definitions. Overall survival was defined as the
time interval between the date of histological diagnosis and the
date of death from any cause [34]. Chemotherapy response was
stratified based on progression-free interval; less than six months to
disease progression was chosen as an end point to define resistant
cases due to its clinical relevance in identifying platinum resistance
[33].
DNA extraction and copy number profiling
Haematoxylin and Eosin stained sections from frozen tissue
were used to evaluate the percentage of tumour cells in tissue
samples. The percentage of tumour cells in the samples in the
Norwegian cohort ranged from 20% to 90% with a median of
70%. In the Norwegian cohort, genomic DNA was extracted from
10–15 serial frozen tissue sections (each 50 mm thick) using
proteinase K digestion and phenol/chloroform in an ABI DNA
extractor (Nucleic Acid Extractor 340A, applied Biosystems,
Carlsbad, CA, USA) following standard protocols. Copy number
profiles of all samples were obtained with the Stanford 42k cDNA
aCGH platform (www.microarray.org/sfgf/jsp/home.jsp; for de-
tails see Materials and Methods S1). Data are stored in the GEO
database with the accession number GSE35783.
Haematoxylin and Eosin stained sections from frozen tissue
were also used to evaluate the percentage of tumour cells in tissue
samples of the Australian cohort. Genomic DNA of samples was
extracted from whole tumour tissue for samples with at least 80%
neoplastic cells. For samples with less than 80% overall tumour
cells needle dissection of serial tumour sections was done to enrich
for epithelial fractions prior to DNA extraction. In the Australian
cohort, DNA was extracted using DNeasy kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. Affymetrix
50 k XbaI single nucleotide polymorphism (SNP) (Affymetrix,
Santa Clara, CA, USA) mapping arrays were applied to obtain
copy number profiles (for details see Materials and Methods S1
and [33]). Data are stored in the GEO database with the accession
number GSE13813.
Segmentation and estimation of copy number data
To segment the copy number data the Piecewise Constant
Fitting (PCF) algorithm [35–37] was applied to log2-transformed
copy number values for each sample. For a given number of
breakpoints, PCF identifies the least-squares optimal segmentation
of the data. The number of breakpoints, and thus the bias-variance
trade-off, is controlled by a penalty parameter cw0 (c~12 in this
study). The least number of probes in a segment was set to 3. For
each segment a corresponding (log2-transformed) segment average
was obtained as the mean the log2-transformed copy number
values for the probes in the segment.
Assessing the genomic instability
The degree of genomic instability in a tumour was quantified by
the total aberration level, using a similar method as described
previously [38]. Let K~ S1,:::,f SRg denote the segmentation
obtained with PCF for a particular sample, where Si is the indices
of the probes belonging to the i’th segment. Let d1,:::,dR designate
the segment length (in nucleotides) and y1,:::,yR the corresponding







Thus, TAI is basically a weighted sum of the segment averages
and represents the absolute deviation from the normal copy
number state, averaged over all genomic locations (for illustration
see Figure S1 and for examples see Figure 1).
Figure 3. Comparison of estimated log copy numbers in the
two cohorts. A total of 2923 genomic loci spaced 1Mb from each
other were defined, and the average estimated log copy number was
found at each loci and in each of the two study cohorts. The resulting
set of 2923 pairs of averages is shown in the figure, suggesting
considerable consistency between the two study cohorts.
doi:10.1371/journal.pone.0054356.g003
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Survival analysis
The Kaplan-Meier estimator and the log-rank test were used to
obtain survival curves and to compare survival rates in patients
with TAI below and above the median. To investigate the
relationship between survival and TAI as a continuous variable,
Cox proportional hazard models were fitted with TAI as the
predictor. Analyses were performed separately on the Norwegian
and Australian cohort.
All computations were performed using the statistical system R
(v 2.12.2).
Mutation testing
Comprehensive germ-line testing for the Australian cohort was
completed in a certified diagnostic pathology laboratory using
sequencing and multiplex ligation-dependent probe amplification
[39].
Figure 4. Survival analysis in relation to genomic instability. Kaplan-Meier survival curves illustrating progression-free survival (PFS) and
overall survival (OS) time (in months) for serous ovarian cancers patients with Total Aberration Index (TAI) above and below the median in the
Norwegian cohort (above) and the Australian cohort (below). Test results are based on log-rank tests. Note that high TAI implies a significant survival
advantage, both with regard to progression-free survival and to overall survival in the Norwegian cohort, as well as for overall survival in the
Australian cohort.
doi:10.1371/journal.pone.0054356.g004





of data Log-rank Cox Log-rank Cox




p = 0.018 p= 0.001
Australia P= 0.263 HR = 0.91
[0.70, 1.20]
p = 0.030 HR= 0.69
[0.51, 0.95]
p = 0.498 p= 0.022
Log-rank: Log-rank tests comparing groups with above and below median TAI.
Cox: Cox proportional hazard regression with TAI as continuous variable.
HR: Hazard ratio with 95% confidence interval for an increase in TAI of 1SD.
doi:10.1371/journal.pone.0054356.t002
Genomic Instability in Ovarian Cancer
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e54356
Results
Frequency of aberrations
The analysis of copy number data in serous ovarian cancers
revealed that the aberrations in the Norwegian and Australian
cohorts were broadly concordant (Figure 2 and Figure 3), with the
most frequent gains occurring on chromosome arms 1q, 3q, 8q,
and 20q, and the most frequent losses occurring on chromosome
arms 4q, 5q, 6 p, 8 p, 13, 16q, 18q, and the whole of the X
chromosome (Figure 2). In the Australian cohort, additional copy
number gains were observed on 1 p and losses on 17 p and 22q
(Figure 2b). The aberration patterns are also conform to those with
high resolution arrays or sequencing data, reported elsewhere
[7,40].
Survival analysis
Figure 4 shows the analysis of progression-free survival and
overall survival in patients with TAI greater or less than the
median for the Norwegian cohort (median = 0.135) and Australian
cohort (median = 0.242), respectively. In the Norwegian cohort,
the group with TAI above the median had markedly increased
progression-free survival (p = 0.024) and overall survival
(p,0.001). In the Australian cohort, patients with TAI above
the median had significantly increased overall survival (p = 0.030),
while the progression-free survival was moderately, but non-
significantly, prolonged. These results were confirmed by univar-
iate Cox analysis, using TAI as a continuous variable (Table 2). In
multivariate Cox analysis, which also included the variables age,
stage, and grade; however, TAI was the only significant variable
for both the Norwegian and Australian cohorts, suggesting that
TAI is an independent predictor of clinical outcome (data not
shown).
Genomic instability in relation to clinicopathological
characteristics and mutation status
The clinicopathological characteristics age, stage, grade, che-
motherapy response (stratified based on progression-free interval),
and progression were analyzed in relation to differences in
genomic instability (Table 1). Patients in the Norwegian cohort
with TAI above the median showed a significantly (p = 0.043)
higher sensitivity to chemotherapy compared to patients with TAI
below the median. No other clinicopathological criteria were
significantly different in the high or low TAI groups in the
Norwegian cohort. In the Australian cohort, none of the
investigated clinicopathological characteristics resulted in signifi-
cant differences with regard to disparities in genomic instability.
Given that a germline mutation in either BRCA1 or BRCA2 in
SOC patients is associated with favourable clinical outcome
[39,41,42], and that these genes are involved in genome integrity,
we tested whether TAI was a surrogate marker for carrier status.
For the 35 patients in the Australian cohort with available BRCA1
and BRCA2 mutation status the germline carrier status was not
significantly associated with the extent of genomic instability (using
Fisher’s exact test). Average TAI was 0.28 (SD = 0.06) for patients
with germline mutation in BRCA1 (n = 6), 0.27 (0.05) for patients
with mutation in BRCA2 (n = 2), 0.22 (0.03) for patients with
unclassified variants of BRCA genes (n = 3), and 0.25 (0.05) for
patients with wild type BRCA genes (n = 24).
Discussion
We investigated the association between genomic instability and
survival of predominantly high-grade SOC in two independent
study cohorts from Norway and Australia and found that patients
with high level of genomic instability, as measured by TAI, had a
more favourable outcome. The results were confirmed by univariate
and multivariate Cox analysis, were TAI was included as a
continuous variable. The aberration patterns in the two cohorts,
determined by two different gene-centred platforms, were highly
concordant and consistent with those reported by others [14,15,20]
and with data from The Cancer Genome Atlas project [7].
Only few publications have investigated the relationship
between complex rearrangements and survival in ovarian cancer.
A previous study, primarily focused on breast cancer but also
considering ovarian tumours, provided some evidence that high
levels of rearrangement in tumours may lead to better clinical
outcome [28]. However, in that study genomic instability was
based on the average expression of 70 genes that correlated with
‘‘total functional aneuploidy’’.
The presented study is based on the analysis of high-resolution
DNA copy number data and the application of a robust and easily
interpretable measure of genomic instability (TAI). TAI assesses
the deviation of the estimated copy number curve from the zero-
line (Figure S1), and thus represents a numeric measure of the
abundance and genomic size of copy number changes in a
tumour. Low-grade ovarian tumours usually carry few genomic
aberrations [43]; however, a small number of short aberrations in
vital genes may be essential for initiating tumour development and
progression. Such short aberrations have low impact on TAI
making the index less suitable for studying initial steps in tumour
development, but rather for quantifying the wide-spread genomic
disorganization that may occur at a later stage of tumour
progression. In the current work, we are considering advanced
ovarian cancer with the aim of examining the importance of broad
aberrations on survival and for this purpose TAI appears as a
suitable way of obtaining numerical quantifications to be used in
statistical analysis.
Genomic instability causes disturbed mitoses, segregation, and
spindle assembly (see reviews by [44–46]). In ovarian cancer, as in
other cancer types, genomic instability and copy number
alterations have been associated with poor prognosis. However,
recent publications have stated that high levels of genomic
instability may be beneficial for the survival and prognosis of
patients in some tumour types [28–30]. Furthermore, elevating the
frequency of genomic instability has been proposed as a strategy to
kill cancer cells [26].
It is thus possible that the initial growth advantage of cancer
cells, based on the transforming effect of genomic instability,
becomes a net disadvantage for the cancer cells, when the well-
organized regulatory system is devastated. The capability for DNA
repair may be reduced, leading to an increased sensitivity to DNA
damaging agents, including chemotherapeutic drugs, such as
cisplatin (see review by [47]). However, most patients are usually
treated with adjuvant chemotherapy making it difficult to
determine whether the observed association of genomic instability
to patient survival is a result of intrinsically less fit cancer cells or
the inability of the tumour cells to repair DNA damages caused by
chemotherapeutic drugs. Thus, it is an interesting observation that
in the Norwegian cohort the patients with a high degree of
genomic instability showed a significantly better response to
platinum-based chemotherapy.
SOC patients with germline mutations in BRCA1 and BRCA2
are more sensitive to chemotherapy and have improved survival
[39,41,42]. In addition, an even higher fraction of ovarian cancer
patients have somatic aberrations in the BRCA genes or the BRCA-
pathway, characterising the phenotype called BRCA-ness [48]. A
number of patients (n = 35) in the Australian cohort were analysed
for germline BRCA-mutations. No significant difference in the
Genomic Instability in Ovarian Cancer
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TAI-index was observed between the BRCA-mutated samples and
others, a finding that is consistent with the TCGA analysis of
BRCA1/2 mutation and ploidy in a large series of SOC
[39,41,42]. Germline status may only be represented in a fraction
of the total homologous recombination dysfunction observed in
the entire cohort, therefore making it difficult to associate
homologous recombination deficiency with the extent of genomic
aberration in tumours [7].
Precise delineation of the negative and positive effects of genomic
instability on cancer cells is of potentially great importance for
tumour classification, survival prediction, and individualized
therapy [49]. However, the mechanisms of genomic instability
transforming the initial advantageous effects on cancer cell survival
into disadvantageous outcome are still unknown, likewise, how these
mechanisms have potential influence on drug efficiency. Further
studies, including other cancer types, are necessary to validate and
refine the presented findings before the biological and clinical
significance of genomic instability may be determined.
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